# Levels of Prevention and Screening: Primordial to Tertiary, Lead Time, Sensitivity, Specificity, PPV (NEET PG PSM)

Source: https://tracknation.in/story/levels-of-prevention-and-screening-primordial-to-tertiary-lead-time-sensitivity-specificity-ppv-neet-pg-psm (TrackNation — free UPSC notes with PYQs)

> NEET PG Community Medicine: primordial, primary, secondary and tertiary prevention on the natural history of disease (with a diagram), population vs high-risk strategy and the prevention paradox, types of screening, WHO criteria for a screening programme, lead time, lead-time and length bias, sensitivity, specificity, predictive values and how prevalence changes PPV — with worked numbers, verified MCQs and revision cards.

## Start Here

🎯 **Exam priority: High-yield (Tier 1).** *Classic one-liners ("rehabilitation is which level?", "screening is which level?",
"what does high prevalence do to PPV?") plus short calculations. Every row below was checked against WHO's Basic Epidemiology*.

CBME mapping: **CM 1** (levels of prevention), **CM 7–8** (screening).

## The Four Levels of Prevention

*The four levels of prevention placed on the natural history of disease. Secondary prevention acts in the window between biological onset and the usual time of diagnosis; screening shifts diagnosis earlier by the lead time.*

| **Level**

 | **Phase of disease**

 | **Aim**

 | **Examples**

 | **Target**

 |
| Primordial

 | Underlying social, economic, environmental conditions

 | Avoid the emergence of risk factors and unhealthy patterns of living

 | National nutrition policy, tobacco taxation, city planning for active transport

 | Total population or selected groups

 |
| Primary

 | Specific causal factors present, disease not yet begun

 | Reduce incidence

 | Immunization, nutrition, removing environmental risks, smoking cessation

 | Total population, groups or high-risk individuals

 |
| Secondary

 | Early disease (onset to the usual time of diagnosis)

 | Reduce prevalence by shortening duration; stop progression

 | Screening, early diagnosis and treatment (cervical screening, BP screening, school eye and hearing tests)

 | Individuals with early disease

 |
| Tertiary

 | Late or established disease

 | Reduce complications, impairment and disability

 | Treatment, rehabilitation (stroke, polio, blindness)

 | Patients

 |

- **Primordial** prevention tackles the social, economic and cultural patterns that raise risk before risk factors appear
— for example national nutrition policy or reducing tobacco use through taxation and price.

- **Primary** prevention lowers incidence by controlling specific causes and risk factors.

- **Secondary** prevention works between onset and the usual time of diagnosis and lowers **prevalence** by
shortening duration. It needs a disease with an early, detectable, treatable phase, a safe accurate test and an effective intervention.

- **Tertiary** prevention reduces the progress and complications of established disease — rehabilitation after polio,
stroke, injury or blindness.

## Population Strategy, High-Risk Strategy and the Prevention Paradox

- **Population (mass) strategy**: shift the whole distribution of a risk factor (blood pressure, cholesterol) slightly
lower. No need to identify the high-risk group; most cases arise in the large middle of the distribution.

- **Prevention paradox**: a measure that brings large benefits to the community offers little to each individual —
most people wear seat-belts all their lives without ever being in a crash.

- **High-risk individual strategy**: target those above a cut-off (e.g. smoking-cessation programmes for smokers). Efficient
for those at greatest risk, but they may contribute little to the total burden.

## Screening: Definition, Types and Criteria

**Screening** is the use of tests on a large scale to identify disease (or risk factors) in apparently healthy people. A positive
screening test is not a diagnosis — it needs individual follow-up.

| **Type**

 | **What it means**

 |
| Mass screening

 | Screening the whole population, or a large subset

 |
| Multiple / multiphasic

 | Several screening tests applied at the same time

 |
| Targeted

 | Groups with specific exposures, e.g. lead-battery workers — common in occupational health

 |
| Case-finding / opportunistic

 | Screening patients who consult a doctor for some other reason

 |

| **Area**

 | **WHO requirement for a screening programme**

 |
| Disorder

 | Well-defined; known prevalence

 |
| Natural history

 | Long period between first signs and overt disease; medically important; an effective remedy exists

 |
| Test

 | Simple and safe; distribution of test values in affected and unaffected people known

 |
| Finance and facilities

 | Cost-effective; facilities available or easily provided

 |
| Acceptability and equity

 | Follow-up after a positive result agreed and acceptable; equitable access; safe effective treatment available

 |

- Low prevalence does not rule screening out if the consequences are serious: newborn screening for **phenylketonuria** is
cost-effective even though the disease is rare, because a special diet allows normal development.

- **Lead time** = the interval between the time a disease can first be detected by screening and the time it is usually
diagnosed. Screening helps only if the lead time is reasonably long — noise-induced hearing loss has a very long lead time, pancreatic
cancer a short one.

## Validity of a Screening Test

| ****

 | **Disease present**

 | **Disease absent**

 |
| Test positive

 | a — true positive

 | b — false positive

 |
| Test negative

 | c — false negative

 | d — true negative

 |

- **Sensitivity** = a/(a+c): when the disease is present, how often the test detects it.

- **Specificity** = d/(b+d): when the disease is absent, how often the test is negative.

- **Positive predictive value** = a/(a+b); **negative predictive value** = d/(c+d).

- A test is **reliable** if it gives consistent results and **valid** if it classifies people correctly
(measured by sensitivity and specificity).

- **The trade-off**: loosening the criteria for a positive test raises sensitivity but lowers specificity; tightening them
does the reverse. For a serious condition in newborns we accept lower specificity to get high sensitivity.

### Worked example — why prevalence changes PPV

| **Population of 10,000 (test: sensitivity 90%, specificity 95%)**

 | **Prevalence 10%**

 | **Prevalence 1%**

 |
| People with the disease

 | 1,000

 | 100

 |
| True positives (90%)

 | 900

 | 90

 |
| False positives (5% of the healthy)

 | 450

 | 495

 |
| Positive predictive value

 | 67%

 | 15%

 |

The same test gives a PPV of 67% where the disease is common and only 15% where it is rare, because false positives
come from the much larger healthy group. Sensitivity and specificity do not change; predictive values do.

## Biases That Make Screening Look Better Than It Is

- **Lead-time bias**: screening finds a disease earlier, but if the earlier diagnosis does not change its course,
survival measured from diagnosis looks longer without anyone living longer.

- **Length bias**: screening preferentially picks up slower-growing, less aggressive disease, which spends longer in the
detectable pre-symptomatic phase — so screen-detected cases look milder.

- The fair test of a screening programme is a fall in **mortality** in a randomized trial, not longer survival after diagnosis.

- Note: WHO's *Basic Epidemiology* uses "length/time bias" for the situation where earlier diagnosis only lengthens the time a
person knows of the disease; the definitions above follow the U.S. National Cancer Institute.

## Rapid-Revision Cards

- Prevent risk factors from emerging — policy, taxation, health promotion.

- Incidence (immunization, nutrition, removing environmental risks).

- Prevalence, by shortening duration — screening, early treatment.

- Limit complications and disability — treatment, rehabilitation.

- Big community benefit, little benefit to most individuals (seat-belts).

- Large-scale tests to detect disease in apparently healthy people.

- Opportunistic screening of patients attending for another reason.

- Several tests at the same time.

- Time from screen-detectability to usual diagnosis.

- Noise-induced hearing loss (long); pancreatic cancer (short).

- a/(a+c) · d/(b+d).

- a/(a+b) · d/(c+d).

- PPV falls; sensitivity and specificity unchanged.

- Earlier diagnosis inflates survival without changing outcome.

- Screening over-detects slow-growing disease.

## Sources

## Sources

*Facts in this article were checked against these documents.*

- Basic Epidemiology, 2nd ed. — Chapter 6: Epidemiology and prevention (levels of prevention, screening) — World Health Organization, 2006 (link)

- Crunching numbers: what cancer screening statistics really tell us — U.S. National Cancer Institute, web page, accessed 2026-10-24 (link)

- CBME Curriculum 2024, Vol. II — Community Medicine (CM 1, CM 7, CM 8) — National Medical Commission, 2024

## Test Yourself: Practice Questions

Sixteen questions in NEET PG style.

## Practice Questions (NEET PG pattern)

*Original questions written in the style of the exam: +4 for a correct answer, −1 for a wrong one. Every answer
was checked against the sources listed above. NEET PG papers are not published by NBEMS, so these are not past-paper questions.*

**Q1.** A government raises tobacco taxes to stop young people from ever taking up smoking. This is

- (a) primordial prevention

- (b) primary prevention

- (c) secondary prevention

- (d) tertiary prevention

**Answer: (a)** — Primordial prevention prevents the emergence of the social, economic and cultural patterns that raise risk; WHO cites tobacco taxation as an example.

**Q2.** Immunization of children against measles is an example of

- (a) primary prevention

- (b) secondary prevention

- (c) tertiary prevention

- (d) primordial prevention

**Answer: (a)** — Primary prevention limits incidence by controlling specific causes; immunization is WHO's example.

**Q3.** Pap-smear screening of women aged 30–60 is primarily

- (a) secondary prevention

- (b) primordial prevention

- (c) primary prevention

- (d) tertiary prevention

**Answer: (a)** — Secondary prevention aims at early detection and treatment between onset and the usual time of diagnosis; WHO uses cervical cancer screening as its example.

**Q4.** Secondary prevention mainly aims to reduce the

- (a) incidence of disease

- (b) emergence of risk factors

- (c) prevalence of disease

- (d) number of births

**Answer: (c)** — By shortening duration through early diagnosis and treatment, secondary prevention reduces prevalence.

**Q5.** Physiotherapy and vocational training for a stroke survivor are examples of

- (a) primary prevention

- (b) tertiary prevention

- (c) secondary prevention

- (d) primordial prevention

**Answer: (b)** — Tertiary prevention reduces the progress or complications of established disease, including rehabilitation.

**Q6.** Seat-belt laws benefit the population greatly but most individuals who wear seat-belts never gain from them. This is the

- (a) ecological fallacy

- (b) lead-time bias

- (c) prevention paradox

- (d) iceberg phenomenon

**Answer: (c)** — WHO describes this as the prevention paradox.

**Q7.** A doctor measures the blood pressure of every adult who visits the clinic for a cough. This is

- (a) targeted screening

- (b) multiphasic screening

- (c) case-finding (opportunistic) screening

- (d) mass screening

**Answer: (c)** — Case-finding or opportunistic screening is aimed at patients who consult a practitioner for another reason.

**Q8.** Applying several screening tests at the same time to the same group is called

- (a) selective screening only

- (b) targeted screening

- (c) case-finding

- (d) multiphasic screening

**Answer: (d)** — Multiple or multiphasic screening uses several screening tests at the same time.

**Q9.** The interval between the time a disease can be detected by screening and the time it is usually diagnosed is the

- (a) latent period of infection

- (b) lead time

- (c) incubation period

- (d) window period

**Answer: (b)** — WHO defines lead time as this interval and requires a reasonably long lead time for screening to help.

**Q10.** For which condition is screening least useful because the lead time is usually short?

- (a) Cervical cancer

- (b) Phenylketonuria

- (c) Noise-induced hearing loss

- (d) Pancreatic cancer

**Answer: (d)** — WHO contrasts noise-induced hearing loss (very long lead time) with pancreatic cancer (usually short).

**Q11.** The proportion of people without the disease who test negative is the

- (a) negative predictive value

- (b) positive predictive value

- (c) sensitivity

- (d) specificity

**Answer: (d)** — Specificity = d/(b+d): when the disease is absent, how often the test is negative.

**Q12.** Lowering the cut-off for a positive test (making the criteria less strict) will usually

- (a) decrease sensitivity and increase specificity

- (b) leave both unchanged

- (c) increase both sensitivity and specificity

- (d) increase sensitivity and decrease specificity

**Answer: (d)** — Reducing the strictness of the criteria increases sensitivity but reduces specificity, and vice versa.

**Q13.** The negative predictive value of a test is

- (a) d/(c+d)

- (b) d/(b+d)

- (c) a/(a+b)

- (d) a/(a+c)

**Answer: (a)** — NPV = probability of not having the disease when the test is negative = d/(c+d).

**Q14.** A test with sensitivity 90% and specificity 95% is used where prevalence is 1%. Its positive predictive value is closest to

- (a) 95%

- (b) 90%

- (c) 15%

- (d) 67%

**Answer: (c)** — In 10,000 people: 90 true positives and 495 false positives, so PPV = 90/585 ≈ 15%. At 10% prevalence the same test gives 67%.

**Q15.** Screening detects a disproportionate number of slow-growing, less aggressive cancers. This is called

- (a) lead-time bias

- (b) recall bias

- (c) length bias

- (d) observer bias

**Answer: (c)** — Length bias: screening is more likely to pick up slower-growing cancers that stay longer in the detectable pre-symptomatic phase.

**Q16.** Newborn screening for phenylketonuria is justified despite the disease's rarity mainly because

- (a) it is a notifiable disease

- (b) the test is always 100% sensitive

- (c) the disease has a short lead time

- (d) early dietary treatment prevents serious, lifelong disability

**Answer: (d)** — WHO notes PKU screening is highly cost-effective because a special diet from birth allows normal development.

### Active Recall

From memory, draw the natural-history line and place the four levels of prevention on it with one example each; then write the formulas for sensitivity, specificity, PPV and NPV and explain why PPV falls when prevalence falls.